Non-targeted Metabolomic Biomarkers and Metabotypes of Type 2 Diabetes: A Cross-sectional Study of PREDIMED Trial Participants
Overview
Authors
Affiliations
Aim: To characterize the urinary metabolomic fingerprint and multi-metabolite signature associated with type 2 diabetes (T2D), and to classify the population into metabotypes related to T2D.
Methods: A metabolomics analysis using the H-NMR-based, non-targeted metabolomic approach was conducted to determine the urinary metabolomic fingerprint of T2D compared with non-T2D participants in the PREDIMED trial. The discriminant metabolite fingerprint was subjected to logistic regression analysis and ROC analyses to establish and to assess the multi-metabolite signature of T2D prevalence, respectively. Metabotypes associated with T2D were identified using the k-means algorithm.
Results: A total of 33 metabolites were significantly different (P<0.05) between T2D and non-T2D participants. The multi-metabolite signature of T2D comprised high levels of methylsuccinate, alanine, dimethylglycine and guanidoacetate, and reduced levels of glutamine, methylguanidine, 3-hydroxymandelate and hippurate, and had a 96.4% AUC, which was higher than the metabolites on their own and glucose. Amino-acid and carbohydrate metabolism were the main metabolic alterations in T2D, and various metabotypes were identified in the studied population. Among T2D participants, those with a metabotype of higher levels of phenylalanine, phenylacetylglutamine, p-cresol and acetoacetate had significantly higher levels of plasma glucose.
Conclusion: The multi-metabolite signature of T2D highlights the altered metabolic fingerprint associated mainly with amino-acid, carbohydrate and microbiota metabolism. Metabotypes identified in this patient population could be related to higher risk of long-term cardiovascular events and therefore require further studies. Metabolomics is a useful tool for elucidating the metabolic complexity and interindividual variation in T2D towards the development of stratified precision nutrition and medicine. Trial registration at www.controlled-trials.com: ISRCTN35739639.
Low-Molecular-Weight Compounds Produced by the Intestinal Microbiota and Cardiovascular Disease.
Cuervo L, McAlpine P, Olano C, Fernandez J, Lombo F Int J Mol Sci. 2024; 25(19).
PMID: 39408727 PMC: 11477366. DOI: 10.3390/ijms251910397.
Zheng X, Zhang W, Wan X, Lv X, Lin P, Si S BMC Nutr. 2024; 10(1):59.
PMID: 38641818 PMC: 11027355. DOI: 10.1186/s40795-024-00836-y.
Zhang F, Chen X, Yang M, Shen X, Wang Y, Zhong D PLoS One. 2024; 19(3):e0300593.
PMID: 38517904 PMC: 10959348. DOI: 10.1371/journal.pone.0300593.
Doumatey A, Shriner D, Zhou J, Lei L, Chen G, Oluwasola-Taiwo O Genome Med. 2024; 16(1):38.
PMID: 38444015 PMC: 10913364. DOI: 10.1186/s13073-024-01308-5.
Ou H, Kawaguchi S, Sonomura K, Kawaguchi T, Kitada S, Yoshiji S Sci Rep. 2023; 13(1):13926.
PMID: 37626071 PMC: 10457396. DOI: 10.1038/s41598-023-40697-2.